Most important in brief
- The list includes osimertinib, alectinib, lorlatinib, dabrafenib with trametinib, and immunotherapy.
- The list does not say for which disease a medicine is paid; your care team clarifies this with the fund.
- Chemotherapy, brigatinib, crizotinib and durvalumab are not on it, and there is no medicine against KRAS G12C.
What applies now
List of the FSDKSH health insurance fund, decision no. 324 of 6 May 2026 · Official Gazette no. 100/2026 (PDF) · checked on 16 November 2026
Cancer medicines are on List I and are dispensed by hospital pharmacies, 90 to 100 percent paid. The 2026 list includes:
- EGFR: osimertinib
- ALK: alectinib, lorlatinib
- BRAF V600E: dabrafenib, trametinib
- Immunotherapy: pembrolizumab, nivolumab, ipilimumab, atezolizumab
The list does not say for which disease a medicine is paid. Your care team clarifies with the fund whether it applies to you.
Not on the list
Chemotherapy, older EGFR tablets, brigatinib, crizotinib, durvalumab, and no medicine against KRAS G12C, ROS1, RET, MET, NTRK or HER2.
What is not publicly known
How hospitals provide chemotherapy and who applies for a treatment is not publicly described. Ask your care team.
What this means for you
If you are treated in Albania, osimertinib, two ALK tablets, dabrafenib with trametinib and immunotherapy are on the list; hospital pharmacies dispense them. The list does not say for which disease. Your care team clarifies with the fund whether it applies to you.
How hospitals provide chemotherapy is not publicly described. Ask about it before treatment starts.